These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
354 related items for PubMed ID: 19241832
1. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer]. Topuzov ME, Prialukhin AE, Zhivov AV, Plekhanov AIu. Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832 [Abstract] [Full Text] [Related]
2. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL. Nakano Y, Okamura K, Takamura S, Okamoto N, Narishima M, Yoshino Y, Hattori R, Ono Y, Ohshima S, Nagasaka T. Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045 [Abstract] [Full Text] [Related]
3. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases. Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F. Ann Clin Lab Sci; 2003 Aug; 33(3):320-3. PubMed ID: 12956448 [Abstract] [Full Text] [Related]
4. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer. Yamanaka K, Yamada Y, Kobayashi Y, Ueno K, Takechi Y, Hasegawa E, Chikahira Y. Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773 [Abstract] [Full Text] [Related]
8. [Value of prostate specific antigen in early diagnosis of prostatic cancer]. Xiao LP, Bi XJ, Li YN, Chen XQ, Zhang XF, Yu XP, Liu G, Yang MC, Song Z. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162 [Abstract] [Full Text] [Related]
9. Prostate-specific antigen: current status. Lukes M, Urban M, Záleský M, Zachoval R, Herácek J, Zdárský E. Folia Biol (Praha); 2001 Jan; 47(2):41-9. PubMed ID: 11321246 [Abstract] [Full Text] [Related]
11. [Prostate-specific antigen and its related parameters in detecting prostate cancer]. Kuruma H, Egawa S. Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698 [Abstract] [Full Text] [Related]
12. Hepatocyte growth factor and interleukin-6 in combination with prostate volume are possible prostate cancer tumor markers in patients with gray-zone PSA levels. Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Namba Y, Kishikawa H, Takahara S, Ichikawa Y. Prostate Cancer Prostatic Dis; 2008 Jan; 11(3):258-63. PubMed ID: 17876341 [Abstract] [Full Text] [Related]
13. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer. Shimbo M, Tomioka S, Sasaki M, Shima T, Suzuki N, Murakami S, Nakatsu H, Shimazaki J. Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994 [Abstract] [Full Text] [Related]
17. New circulating biomarkers for prostate cancer. Bensalah K, Lotan Y, Karam JA, Shariat SF. Prostate Cancer Prostatic Dis; 2008 Aug; 11(2):112-20. PubMed ID: 17998918 [Abstract] [Full Text] [Related]